Drugs Made In America Acquisition DMIIR
NASDAQ DMIIR
$0.07 -0.01 (-7.04%)
As of: Sep 2, 2026 · 12:48 PM EDT

Drugs Made In America Acquisition (DMIIR) Non-Current Deffered Revenue (2025 - 2026)

Drugs Made In America Acquisition (DMIIR) posted quarterly Non-Current Deffered Revenue of $17.5 million for Q4 2025, little changed quarter-over-quarter from $17.5 million in Q3 2025.

Analysis

Drugs Made In America Acquisition (DMIIR) Non-Current Deffered Revenue (2025 - 2026) Analysis & Trends

Drugs Made In America Acquisition (DMIIR) has reported Non-Current Deffered Revenue for 1 consecutive years, with $17.5 million the latest figure, recorded in Q4 2025.

  • In Q4 2025, Non-Current Deffered Revenue changed N/A year-over-year to $17.5 million; the TTM figure through Dec 2025 stood at $17.5 million (changed N/A YoY), while the FY2025 annual figure was $17.5 million, changed N/A from the prior year.
  • Non-Current Deffered Revenue held at $17.5 million in Q4 2025 per DMIIR's latest filing, from $17.5 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $17.5 million in Q3 2025 and bottomed at $17.5 million in Q3 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Deffered Revenue (Qtr)
1 Cluster Group Holdings 8.00 Bn 8.00 Bn - -
2 Agriculture & Natural Solutions Acquisition 853.42 Mn 853.17 Mn - 12.08 Mn
3 K&F Growth Acquisition 836.15 Mn 836.15 Mn - 10.06 Mn
4 Armada Acquisition 666.23 Mn 666.18 Mn - 9.20 Mn
5 Pioneer Acquisition I 652.74 Mn 652.27 Mn - 12.05 Mn
6 Oxley Bridge Acquisition 652.11 Mn 652.11 Mn - -
7 Titan Acquisition 651.43 Mn 941.85 Mn - 13.14 Mn
8 GSR IV Acquisition 622.22 Mn 622.22 Mn - 9.20 Mn
9 Launch One Acquisition 618.70 Mn 618.70 Mn - -
10 Drugs Made In America Acquisition 5.10 Mn 5.10 Mn - 17.50 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 17.50 Mn
Dec 31, 2025 17.50 Mn
Sep 30, 2025 17.50 Mn